Brief: Brainstorm Cell Therapeutics Inc Says FDA Advisory Committee (Meeting To Review Nurown For Als
27/09/2023 12:04
Sept 27 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM CELL THERAPEUTICS INC - FDA ADVISORY COMMITTEE
(ADCOM) MEETING TO REVIEW NUROWN(®) FOR ALS
* BRAINSTORM CELL THERAPEUTICS INC - BLA FOR NUROWN(®) HAS A
PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE TARGETED TO
OCCUR BY DECEMBER 8, 2023
Source text for Eikon: ID:nPn9NvxRSa
Further company coverage: BCLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview